BioStock: Ultimovacs enters next step in new vaccine platform development
Ultimovacs’ TENDU trial is a clinical phase I study aimed at testing the company’s TET platform for cancer vaccine development in prostate cancer patients. The study was initiated earlier this year with the first cohort of patients; now the company has announced dosing the first patient in the second of three cohorts for the TENDU study.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.